Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.25) by 76.19 percent. This is a 85 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $24.741 million which beat the analyst consensus estimate of $5.595 million by 342.20 percent. This is a 19.16 percent decrease over sales of $30.604 million the same period last year.